Registered business · FR · Founded 2007 · Accounts through 2023 · Updated Jul 27, 2026
See what is holding the value back today, what this company could be worth in five years and which actions make the difference. The estimate is based on filed annual accounts.
Is this your company? Claim and manage this profile
Historical rounded range based on the latest available public filing for fiscal year 2023. This is not a current market value or asking price.
Based on filed company accountsThe historical valuation curve is public. Create a free account for the future five-year growth forecast, the insights behind it, and concrete action points that can increase this company’s value.
Free account · private workspace
Public filings are a starting point. Owner-confirmed accounts, net debt, leases and commercial context can refine the range for a sale, financing or transfer.
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
Register your interest privately. Upswitch reviews every request and keeps it queued until a safe, verified owner contact route is available.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Claim this companyCROSSFIT HEM is a business in NACE sector 93.13 based in France. The company was founded in 2007.
CROSSFIT HEM is listed in French National Business Register (RNE/INPI) under registry number 493562839. The public employee band is 01, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 93.13 band file annual accounts with INPI.
Across the 2019-2023 window revenue has grown, moving from €94,335 to €128,769.
The most recent annual filing covers 2023 (period end 2023-12-31).
If you are researching CROSSFIT HEM for acquisition, investment, or due-diligence purposes, this page consolidates its firmographics, multi-year filings, and a historical indicative range based on the latest available public filing, not a current market value.
Public regulator-filed figures across 2 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202331 Dec 2023 | €128,769 | - | €83,291 | €59,651 | - |
| 201931 Dec 2019 | €94,335 | - | €131,476 | €64,682 | - |
CROSSFIT HEM was founded in 2007 and is registered with French National Business Register (RNE/INPI).
CROSSFIT HEM is registered under NACE 93.13. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2023 (period end 2023-12-31), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded historical indicative range for CROSSFIT HEM, based on the latest available public filing for fiscal year 2023. It is not a current market value, asking price, certified or statutory valuation, or financial, investment, tax or legal advice. Verify current figures before relying on it for any decision or transaction.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
Indicative public valuation range based on financial year 2023. This historical record does not yet contain an immutable calculation snapshot, so no sector range is reconstructed after the fact. Not a transaction value, asking price or fairness opinion.
